External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC

Inclusion Criteria:

• Must have a diagnosis of locally advanced (non-resectable) or metastatic RET-fusionpositive NSCLC
• Must have received at least one line of systemic therapy for locally advanced (non-resectable) or metastatic RET-fusion positive NSCLC, which may include regimenscontaining:
• Chemotherapy, e.g., regimens containing platinum doublet-based therapy (carboplatin, cisplatin)
• Chemotherapy in combination with other drugs will be assessed, e.g., incombination with pemetrexed, immune checkpoint inhibitors (pembrolizumab),bevacizumab
• Ramucirumab in combination with docetaxel
• Immune checkpoint inhibitors, e.g., pembrolizumab, nivolumab, and atezolizumab
• MKIs, e.g., cabozantinib, alectinib, vandetanib, sunitinib, and nintedanib
• Must be aged ≥18 years of age at the initiation of first systemic line of therapy
• Must have availabile of performance status (e.g., Eastern Cooperative Oncology Group [ECOG] score or Karnofsky score)
• Must have an index date at least 3 months prior to the start of data collection (inorder to include patients with at least 3 months of follow-up after index date),unless date of death occurred less than three months from index date
• Must have an approved waiver of informed consent or signed informed consent forparticipation in the retrospective chart review study, as applicable

Exclusion Criteria:

• Known primary driver alteration other than RET (e.g., targetable mutation in EGFR,ALK, ROS1, or BRAF)
• History of other malignancy, other than non-melanoma skin cancer, within 1 year priorto initiation of first systemic therapy
• Received pralsetinib as the first line of systemic therapy for RET-fusion positiveNSCLC, or prior to initiation of first systemic therapy